Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350645 | 0.81 | GABBR2 (0.38) | CYP2C19CYP1A2CYP2D6CYP3A4MEN1 | |
| SCHEMBL11079771 | 0.80 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1AOC3CYP2C19CYP1A2 | |
| SCHEMBL349306 | 0.78 | GABBR2 (0.56) | CYP2C19CYP1A2CYP2D6CYP3A4MEN1 | |
| SCHEMBL351660 | 0.78 | GABBR2 (0.57) | CYP2C19CYP1A2CYP2D6SLC6A4SLC6A3 | |
| SCHEMBL350711 | 0.78 | GABBR2 (0.56) | CYP2C19CYP1A2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL5652935 | 0.75 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1AOC3CYP2C19CYP1A2 | |
| SCHEMBL21465820 | 0.75 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1AOC3CYP2C19CYP1A2 | |
| SCHEMBL10200947 | 0.75 | GABBR2 (0.64) | ALDH1A1L3MBTL1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL350431 | 0.74 | CES2 (0.39) | CYP2C19CYP1A2CYP2D6CYP3A4MEN1 | |
| SCHEMBL341858 | 0.73 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1AOC3CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009646-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | GABBR2, GABBR1, GABRB1 | ALDH1A1 1156/4885L3MBTL1 2986/4885AOC3 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.